|
Number of episodes of IE
|
499
|
957
| |
|
Age (y)
|
62 (28 to 81)
|
67 (31 to 84)
|
0.0002
|
|
Male
|
361 (72)
|
657 (69)
|
NS
|
|
Hemodialysis
|
10 (2)
|
19 (2)
|
NS
|
|
Diabetes mellitus
|
86 (17)
|
182 (19)
|
NS
|
|
HIV infection
|
29 (6)
|
23 (2)
|
0.004
|
|
Cancer
|
46 (9)
|
129 (13)
|
0.03
|
|
Chronic liver disease
|
115 (23)
|
147 (15)
|
0.0005
|
|
Current intravenous drug abuse
|
74 (15)
|
57 (6)
|
0.0001
|
|
Previous IE
|
38 (8)
|
80 (8)
|
NS
|
|
Chronic intravenous access
|
59 (12)
|
95 (10)
|
NS
|
|
Congenital heart disease
|
38 (8)
|
74 (8)
|
NS
|
|
Native valve predisposition
|
132 (26)
|
270 (28)
|
NS
|
|
Nosocomial IE
|
29 (6)
|
50 (5)
|
NS
|
|
Health care associated IE
|
107 (21)
|
227 (24)
|
NS
|
|
Community-acquired IE
|
363 (73)
|
680 (71)
|
NS
|
|
Native vs prosthetic valve
|
385 vs 114
|
732 vs 225
|
NS
|
|
Site of IE (n = 1282)
| |
|
Mitral vs aortic valve
|
166 vs 161
|
329 vs 359
|
NS
|
|
Bivalvular involvement (mitral and aortic)
|
39 (8)
|
78 (8)
|
NS
|
|
Right-sided IE
|
60 (12)
|
29 (3)
|
0.0001
|
|
CIED-IE
|
21 (4)
|
40 (4)
|
NS
|
|
Vegetations (n = 710)‡
| |
|
Size of all vegetations (mm)
|
14 (6 to 30)
|
10 (4 to 26)
|
0.0001
|
|
≥ 10 mm
|
228 (79)
|
264 (63)
|
0.0001
|
|
≥ 15 mm
|
142 (49)
|
145 (35)
|
0.0001
|
|
≥ 20 mm
|
74 (26)
|
78 (19)
|
0.03
|
|
Concomitant therapy at onset of IE
| |
|
Anticoagulants
|
102 (20)
|
228 (24)
|
NS
|
|
Antiaggregants
|
68 (14)
|
103 (11)
|
NS
|
|
Microbiology
| | | |
|
Staphylococcus aureus
|
141 (28)
|
142 (15)
|
0.0001
|
|
Viridans group streptococci
|
66 (13)
|
151 (16)
|
NS
|
|
Coagulase-negative staphylococci
|
52 (10)
|
95 (10)
|
NS
|
|
Enterococcus
species
|
45 (9)
|
137 (1)
|
0.004
|
|
Streptococcus bovis
|
44 (9)
|
98 (10)
|
NS
|
|
Polymicrobial
|
19 (4)
|
32 (3)
|
NS
|
|
Other microorganisms
|
16 (3)
|
45 (6)
|
NS
|
|
Other streptococci
|
16 (3)
|
43 (5)
|
NS
|
|
Fungi/yeasts
|
7 (1)
|
13 (1)
|
NS
|
|
HACEK
|
1 (0.2)
|
2 (0.2)
|
NS
|
|
Microbiology negative
|
92 (18)
|
199 (21)
|
NS
|
